Dianthus Therapeutics, Inc. /DE/
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · All Programs
All Programs
Multiple claseprubart data presentations were made at the 18th International Congress on Neuromuscular Diseases (ICNMD), American Academy of Neurology (AAN) Autoimmune Neurology Conference, American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, and American Neurological Association (ANA) Annual Meeting. Among the data presented were results demonstrating a sustained safety and efficacy profile for claseprubart in the Phase 2 MaGic open-label extension, and a 75% response rate observed in the interim responder analysis of the first 40 participants completing unblinded Part A of the Phase 3 CAPTIVATE trial. Presentations are available in the Investors section of the Dianthus website.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.